目的 探讨血清miR-128和miR-720相对表达量对脑胶质瘤的诊断价值。方法 采用TaqMan MicroRNA Assays Real-time PCR技术检测62名健康对照者、54例低级别脑胶质瘤患者和57例高级别脑胶质瘤患者血清mi-128和mi- 720相对表达量。结果 低级别脑胶质瘤组与健康对照组比较血清mi-720相对表达量差异有统计学意义（P <0. 05), 高级别脑胶质瘤组mi-128和mi-720相对表达量差异均有统计学意义（P <0.05);与低级别脑胶质瘤组比较,高级别脑胶质瘤组的miR-128和miR-720相对表达量差异均有统计学意义（P <0. 05)。miR-128和miR-720联合检测区分健康对照组和脑胶质瘤组的诊断灵敏性和特异性分别为92. 3%和87. 2% ,区分低级别脑胶质瘤组和高级别脑胶质瘤组的诊断灵敏性和特异性分别为84.3%和88.9%。结论血清mi-128和mi-720相对表达量联合诊断为临床脑胶质瘤的诊断和预后提供一种辅助方法。

Objective To explore the diagnostic values of serum miR-128 and miR-720 relative expressions in patients with glioma. Methods The serum miR-128 and miR-720 relative expressions were detected by TaqMan MicroRNA Assays Real-time PCR in 54 low-grade glioma patients group, 57 high grade glioma patients group and 62 healthy controls group. Results Compared to the healthy control group, miR-720 relative expression in patients with low-grade glioma were showed significant difference, miR-128 and miR-720 relative expressions in the high -grade glioma group showed significant difference. Compared to the low-grade glioma group, miR- 128 and miR-720 relative expressions in the high- grade glioma were showed significant difference. The diagnostic sensitivity and specificity of miR-128 and miR-720 relative expressions for discriminating the healthy control group and the glioma group were 92. 3% and 87. 2% , respectively. The diagnostic sensitivity and specificity for discriminating the low-grade glioma group and the high -grade glioma group were 84. 3% and 88. 9%，respectively .Conclusion The combined detection of miR-128 and miR-720 relative expressions may provide an auxiliary method for the clinical diagnosis and classification of glioma.